在从全球基金支持过渡的背景下,衡量阿片类药物激素治疗计划的可持续性
Raminta Stuikyte1, Ivan Varentsov2, Catherine Cook3
1, Vilnius, Lithuania. raminta.stuikyte@gmail.com.
Harm reduction journal
|January 11, 2024
概括
一个新的工具评估了阿片类药物激动剂治疗 (OAT) 计划的可持续性,这对于维持依赖捐助者资金的医疗服务至关重要. 该工具有助于评估和改善OAT计划的弹性和可扩展性.
科学领域:
- 公共卫生 公共卫生
- 医疗保健服务研究 医疗服务研究
- 药物使用障碍 药物使用障碍
背景情况:
- 依赖捐助者的资金对卫生响应的计划和财务可持续性构成重大挑战.
- 现有的以艾滋病毒为重点的可持续性评估不充分解决了阿片类药物激动剂治疗 (OAT) 计划.
- 需要一个专门的工具来评估OAT计划的可持续性.
研究的目的:
- 开发和验证一个专门的工具来评估阿片类药物激动剂治疗 (OAT) 计划的可持续性.
- 为评估OAT服务的弹性和可扩展性提供一个工具.
- 为提高OAT计划的长期可行性制定策略.
主要方法:
- 对现有的艾滋病毒可持续性概念和工具进行了全面的桌面审查.
- 一个国际咨询委员会在整个开发过程中提供了指导.
- 在三个国家进行试点测试和随后的小调整验证了该仪器.
主要成果:
- 该OAT可持续性工具包括一个概念框架,方法指南和一个实施工具.
- 它通过使用联合国和世卫组织的指导来衡量政策和治理,财务和资源以及服务的可持续性.
- 该仪器在三个国家成功试点,并在2023年中期之前在五个国家实施,证明了其实用性.
结论:
- 开发的工具提供了一种全面的方法来审查OAT程序的弹性和可扩展性.
- 它可以为提高OAT计划可持续性的路线图的制定提供信息.
- 虽然该仪器是在东欧和中亚开发的,但可以适应全球使用.
相关概念视频
Opioid Analgesics: Synthetic and Semisynthetic Opioids
300
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
300
Opioid Analgesics: Morphine and Other Natural Cogeners
251
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
251
Analgesia and Pain Management
625
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
625
Opioid Receptors: Overview
847
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
847
Drug Administration and Therapy Phases: Overview
471
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
471
Drug Control Governance: Regulatory Bodies and Their Impact
160
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
160


